The CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) eGFR equation is the most accurate and widely recommended formula for estimating glomerular filtration rate in adults. First published in 2009 and revised in 2021, the CKD-EPI equation calculates an estimated GFR (eGFR) in mL/min/1.73 m² from serum creatinine, age, and sex. The landmark 2021 revision removed the race coefficient that had been present in the original equation, following a systematic review by the NKF-ASN Task Force that found no biological basis for using race as a variable in GFR estimation. eGFR is the cornerstone of chronic kidney disease diagnosis, staging, and management. A value persistently below 60 mL/min/1.73 m² for more than 3 months defines CKD regardless of other markers, while values below 15 indicate kidney failure requiring renal replacement therapy consideration. KDIGO 2012 and subsequent guidelines recommend CKD-EPI over the older MDRD equation because CKD-EPI performs better across the full range of eGFR values, particularly above 60 mL/min/1.73 m², where MDRD systematically underestimates kidney function. eGFR also drives drug dosing decisions, referral thresholds, and cardiovascular risk stratification, making accurate calculation essential in everyday clinical practice. Chronic kidney disease (CKD) affects approximately 850 million people worldwide — more than 10% of the global population — and is a leading cause of cardiovascular death, end-stage renal disease requiring dialysis, and premature mortality. Early detection and accurate staging of CKD is therefore one of the most important tasks in primary care and nephrology. The 2021 CKD-EPI creatinine equation removed the race coefficient from the 2009 version after landmark analyses demonstrated that the original Black race multiplier increased estimated GFR by a factor of 1.159 for Black patients, leading to systematic underestimation of CKD severity and delayed referral for nephrology care and transplant listing in Black populations. The new race-free equation was jointly adopted by NKF and ASN in 2021.
eGFR = 142 × min(Scr/κ, 1)^α × max(Scr/κ, 1)^−1.200 × 0.9938^Age [× 1.012 if female]; κ = 0.7 (female), 0.9 (male); α = −0.241 (female), −0.302 (male)
- 1Collect inputs: serum creatinine (mg/dL), age (years), and sex assigned at birth (male or female).
- 2Select the sex-specific constants: κ is 0.7 for females and 0.9 for males; α is −0.241 for females and −0.302 for males.
- 3Compute the creatinine-to-κ ratio (Scr/κ) and evaluate the two power-law terms: min(Scr/κ, 1)^α captures below-threshold creatinine and max(Scr/κ, 1)^−1.200 captures above-threshold creatinine.
- 4Multiply by 0.9938^Age to account for the natural age-related decline in kidney function.
- 5Apply the female sex multiplier of 1.012 if the patient is female; leave unchanged if male.
- 6Combine all terms: 142 × [min term] × [max term] × [age term] × [sex term] to produce eGFR in mL/min/1.73 m².
- 7Map the result to a CKD stage: G1 ≥90, G2 60–89, G3a 45–59, G3b 30–44, G4 15–29, G5 <15.
Normal kidney function
Scr/κ = 0.8/0.7 = 1.143. min(1.143,1)^−0.241 = 1.000^−0.241 = 1.0. max(1.143,1)^−1.200 = 1.143^−1.200 ≈ 0.838. Age term: 0.9938^32 ≈ 0.820. Female multiplier: 1.012. eGFR = 142 × 1.0 × 0.838 × 0.820 × 1.012 ≈ 99 mL/min/1.73 m². Stage G1 — normal or high.
Mildly to moderately decreased — nephrology referral to be considered
Scr/κ = 1.6/0.9 = 1.778. min term = 1.0^−0.302 = 1.0. max term = 1.778^−1.200 ≈ 0.516. Age term = 0.9938^58 ≈ 0.698. Male, no sex multiplier. eGFR = 142 × 1.0 × 0.516 × 0.698 ≈ 51 mL/min/1.73 m². CKD G3a.
Severely decreased — renal replacement therapy planning warranted
Scr/κ = 3.2/0.7 = 4.571. min term = 1.0. max term = 4.571^−1.200 ≈ 0.166. Age term = 0.9938^74 ≈ 0.635. Sex ×1.012. eGFR = 142 × 0.166 × 0.635 × 1.012 ≈ 15 mL/min/1.73 m².
Mildly decreased — monitor annually with urinalysis
Scr/κ = 1.1/0.9 = 1.222. min term = 1.0. max term = 1.222^−1.200 ≈ 0.822. Age term = 0.9938^45 ≈ 0.757. eGFR = 142 × 0.822 × 0.757 ≈ 79 mL/min/1.73 m². G2 stage.
Diagnosing and staging chronic kidney disease for initiation of nephroprotective therapies (ACE inhibitors, SGLT2 inhibitors). This application is commonly used by professionals who need precise quantitative analysis to support decision-making, budgeting, and strategic planning in their respective fields
Triggering nephrology referral at eGFR thresholds (typically <30 for planning renal replacement therapy). Industry practitioners rely on this calculation to benchmark performance, compare alternatives, and ensure compliance with established standards and regulatory requirements
Guiding medication dose adjustment or contraindication decisions (e.g., metformin contraindicated below eGFR 30). Academic researchers and students use this computation to validate theoretical models, complete coursework assignments, and develop deeper understanding of the underlying mathematical principles
Cardiovascular risk stratification — eGFR <60 independently doubles cardiovascular event risk. Financial analysts and planners incorporate this calculation into their workflow to produce accurate forecasts, evaluate risk scenarios, and present data-driven recommendations to stakeholders
Transplant evaluation — both donor and recipient GFR assessment for living kidney donation eligibility. This application is commonly used by professionals who need precise quantitative analysis to support decision-making, budgeting, and strategic planning in their respective fields
Pregnancy
Standard CKD-EPI equations are not validated in pregnancy. Rising creatinine in pregnancy is always abnormal and warrants urgent evaluation, since normal pregnant creatinine is typically 0.4–0.6 mg/dL.'} When encountering this scenario in ckd epi calculations, users should verify that their input values fall within the expected range for the formula to produce meaningful results. Out-of-range inputs can lead to mathematically valid but practically meaningless outputs that do not reflect real-world conditions.
Amputees and muscle-wasting conditions
{'title': 'Amputees and muscle-wasting conditions', 'body': 'Patients with significant limb amputations or conditions causing profound muscle wasting (cachexia, muscular dystrophy, spinal cord injury) produce less creatinine and will have falsely elevated eGFR. Cystatin C-based GFR or 24-hour urine creatinine clearance should be used instead.'} This edge case frequently arises in professional applications of ckd epi where boundary conditions or extreme values are involved. Practitioners should document when this situation occurs and consider whether alternative calculation methods or adjustment factors are more appropriate for their specific use case.
High dietary meat intake
{'title': 'High dietary meat intake', 'body': 'Consuming large amounts of cooked meat transiently raises serum creatinine by up to 0.3 mg/dL, which can lower calculated eGFR. Blood samples for creatinine ideally should be taken in the fasting state or after avoiding red meat for 12 hours for the most accurate result.'}
Rapidly changing creatinine (AKI)
During acute kidney injury, creatinine may rise 0.5–2.0 mg/dL per day and the equation dramatically underestimates the rate of decline. Never use eGFR to guide management in the acute setting — use absolute creatinine and urine output.'} When encountering this scenario in ckd epi calculations, users should verify that their input values fall within the expected range for the formula to produce meaningful results. Out-of-range inputs can lead to mathematically valid but practically meaningless outputs that do not reflect real-world conditions.
Kidney donors and solitary kidney
{'title': 'Kidney donors and solitary kidney', 'body': 'Individuals with a single kidney (post-donation, trauma, or congenital) have chronically reduced GFR by roughly 30–40%. Their eGFR should be interpreted in this context; values of 50–65 may be expected and appropriate for a healthy single-kidney state rather than indicating CKD.'} This edge case frequently arises in professional applications of ckd epi where boundary conditions or extreme values are involved. Practitioners should document when this situation occurs and consider whether alternative calculation methods or adjustment factors are more appropriate for their specific use case.
| Stage | eGFR (mL/min/1.73 m²) | Description | Action |
|---|---|---|---|
| G1 | ≥ 90 | Normal or high (with other markers) | Monitor; treat underlying cause |
| G2 | 60–89 | Mildly decreased | Annual monitoring; risk factor control |
| G3a | 45–59 | Mildly to moderately decreased | 6-monthly monitoring; consider nephrology |
| G3b | 30–44 | Moderately to severely decreased | Nephrology referral; avoid nephrotoxins |
| G4 | 15–29 | Severely decreased | Nephrology care; plan renal replacement therapy |
| G5 | < 15 | Kidney failure | Dialysis or transplant; conservative care options |
Why was race removed from the 2021 CKD-EPI equation?
The NKF-ASN Task Force found no robust biological justification for using self-reported race as a variable in GFR estimation. The original Black race multiplier (1.159) originated from a statistical observation in a predominantly male dataset and perpetuated health disparities by underestimating CKD severity in Black patients, delaying referral and transplant listing. The 2021 race-free equation performs equally well across racial groups.
How is CKD-EPI different from MDRD?
The MDRD (Modification of Diet in Renal Disease) study equation was derived from a population with established CKD and systematically underestimates eGFR above 60 mL/min/1.73 m². CKD-EPI was developed from a larger, more diverse population spanning the full GFR range and outperforms MDRD at higher eGFR values. KDIGO guidelines now recommend CKD-EPI over MDRD for routine use.
Should I use CKD-EPI or Cockcroft-Gault for drug dosing?
Drug approval studies have historically used Cockcroft-Gault creatinine clearance for dose adjustment thresholds, particularly for renally cleared drugs such as NOACs, aminoglycosides, and metformin. Although CKD-EPI is more accurate for diagnosing and staging CKD, Cockcroft-Gault remains the standard for many pharmacokinetic applications. Always check drug monographs for which equation they specify.
What does an eGFR of 60 mean?
An eGFR of 60 mL/min/1.73 m² represents approximately 60% of average normal kidney function. A single value does not diagnose CKD — the value must be persistently below 60 for at least 3 months to meet the CKD G3a definition. One abnormal result may reflect transient causes such as dehydration, recent contrast exposure, or acute illness.
Is eGFR accurate in very muscular or very thin individuals?
No. CKD-EPI uses serum creatinine, which is generated by muscle metabolism. Bodybuilders produce more creatinine and may have artificially elevated creatinine and falsely low eGFR. Frail, sarcopenic, or malnourished individuals produce less creatinine and may have falsely normal eGFR despite impaired kidney function. In these populations, cystatin C-based GFR estimation or the combined creatinine-cystatin C CKD-EPI equation is preferred.
Can I use eGFR in acute kidney injury?
No. eGFR equations assume a steady state where creatinine production equals elimination. In AKI, creatinine is rising rapidly and does not reflect true GFR. Use the absolute creatinine trend, urine output, and clinical context to assess kidney function in AKI, not a calculated eGFR. This is an important consideration when working with ckd epi calculations in practical applications. The answer depends on the specific input values and the context in which the calculation is being applied.
What is the normal eGFR by age?
eGFR declines naturally with age at approximately 1 mL/min/1.73 m² per year after age 40, due to progressive nephron loss and reduced renal reserve. Average values by decade: age 20–29 ~116, age 30–39 ~107, age 40–49 ~99, age 50–59 ~93, age 60–69 ~85, age 70+ ~75. An eGFR of 65 in a healthy 80-year-old is less alarming than the same value in a 35-year-old.
What should I do if my eGFR is below 60?
A single low eGFR should be repeated after 3 months. If persistently below 60, you have CKD by definition. Management depends on stage and the presence of proteinuria or other markers. G3a with proteinuria warrants nephrology referral. G4 patients should be under nephrology care for preparation for renal replacement therapy. Lifestyle modifications, blood pressure control, and treatment of underlying causes (diabetes, hypertension) are fundamental at all stages.
Pro Tip
Always pair eGFR with a urine albumin-to-creatinine ratio (UACR). A patient with eGFR 75 and UACR >300 mg/g has a dramatically worse prognosis than eGFR 75 with no albuminuria. KDIGO risk stratification uses a combined eGFR + albuminuria heat map, not eGFR alone.
Did you know?
The original 2009 CKD-EPI equation used a race coefficient of 1.159 for Black patients based on a single observational study. When the 2021 race-free equation was validated across 1.2 million patients in 12 countries, it performed equally well across all racial groups — demonstrating that removing the race variable improved rather than harmed accuracy.
References
- ›Inker et al. — New Creatinine and Cystatin C–Based Equations to Estimate GFR without Race (NEJM 2021)
- ›KDIGO 2024 CKD Guideline
- ›Levey et al. — CKD-EPI 2009 (Ann Intern Med 2009)
- ›NKF-ASN Task Force Report on Reassessing the Inclusion of Race in Diagnosing Kidney Disease
- ›NHS — Chronic Kidney Disease Overview